Neuromuscular Blocking Agents

On this page

NMBAs Overview - Blocking the Signal

Neuromuscular Blocking Agents (NMBAs) induce reversible muscle paralysis for procedures (intubation, surgery) by acting at the Neuromuscular Junction (NMJ).

  • Target: Postsynaptic nicotinic acetylcholine receptors ($nAChR$) on the motor endplate.
  • Action: Prevent acetylcholine ($ACh$) from binding or activating $nAChR$, inhibiting muscle depolarization and causing flaccid paralysis.
  • Classification:
    • Depolarizing:
      • e.g., Succinylcholine.
      • $nAChR$ agonist: initial depolarization (fasciculations) then prolonged block.
    • Non-depolarizing:
      • e.g., Rocuronium, Vecuronium.
      • Competitive $nAChR$ antagonists: direct paralysis, no fasciculations.

Neuromuscular Junction & NMBA Action

⭐ Succinylcholine (depolarizing) uniquely causes initial muscle fasciculations before paralysis; non-depolarizing agents do not.

Succinylcholine - The Fast & Furious Blocker

  • Type: Depolarizing NMB; only one in class.
  • Mechanism: AChR agonist at NMJ.
    • Phase I: Fasciculations → paralysis. AChE inhibitors worsen.
    • Phase II (high/repeat dose): NDMB-like block.
  • Kinetics:
    • Onset: 30-60s. Duration: 5-10min.
    • Metabolism: Plasma pseudocholinesterase.
  • Dose (IV): 1-1.5 mg/kg.
  • Use: Rapid Sequence Intubation (RSI).
  • Side Effects:
    • Fasciculations, myalgia.
    • Hyperkalemia ⚠️ (burns >24h, trauma, denervation).
    • ↑IOP, ↑gastric pressure.
    • Malignant Hyperthermia (MH) trigger ⚠️.
    • Bradycardia (children, repeat doses).
    • Prolonged block: pseudocholinesterase deficiency (Dibucaine #).

⭐ Critical risk: severe hyperkalemia in patients with burns (>24-48h), crush injuries, or denervating neuromuscular diseases.

Non-Depolarizing Agents - The Steady Crew

  • Mechanism: Competitive antagonists at nAChRs (NMJ). Prevent ACh binding → no depolarization.

  • Key Agents:

    AgentClassDurationMetabolism/EliminationNotes
    AtracuriumBenzylisoquinoliniumIntermediateHofmann elim., ester hydrolysisCan cause histamine release; Laudanosine metabolite
    CisatracuriumBenzylisoquinoliniumIntermediateHofmann elim. (organ-independent)Minimal histamine; No direct renal/hepatic metabolism
    MivacuriumBenzylisoquinoliniumShortPlasma pseudocholinesteraseHistamine release; duration prolonged if atypical enzyme
    PancuroniumAminosteroidLongRenal excretion (primarily)Vagolytic (↑HR, ↑BP); active metabolites
    VecuroniumAminosteroidIntermediateHepatic metabolism (primarily)Cardiovascularly stable; no histamine release
    RocuroniumAminosteroidIntermediateHepatic metabolism (primarily)Fastest onset of non-depolarizers; minimal histamine
  • General:

    • Slower onset vs Succinylcholine (except high-dose Rocuronium).
    • No fasciculations. 📌
    • Reversal: Anticholinesterases (e.g., Neostigmine + Glycopyrrolate).
    • Specific Reversal: Sugammadex for Rocuronium & Vecuronium.
    • Monitor: Train-of-Four (TOF).

⭐ Cisatracurium: Preferred in renal/hepatic failure due to organ-independent Hofmann elimination.

Reversal & Monitoring - Waking Up & Watching Out

  • Reversal Strategies:
    • Anticholinesterases:
      • Neostigmine: 0.04-0.07 mg/kg. Onset 5-10 min.
      • Pair with Glycopyrrolate (0.01-0.02 mg/kg) to counter muscarinic effects. 📌 Neo+Glyco: Slower onsets match.
    • Sugammadex (SRBA):
      • For Rocuronium/Vecuronium.
      • Dose: 2 mg/kg (TOF count ≥2), 4 mg/kg (PTC 1-2), 16 mg/kg (immediate reversal of Rocuronium 1.2 mg/kg).
  • Neuromuscular Monitoring (PNS):
    • Site: Ulnar nerve (Adductor Pollicis).
    • Train-of-Four (TOF):
      • TOF Ratio (T4/T1) target > 0.9 for safe extubation.
    • Double Burst Stimulation (DBS): Easier manual fade detection.
    • Post-Tetanic Count (PTC): For deep blocks (no TOF response).
  • Waking Up & Watching Out:
    • Prevent Residual Neuromuscular Blockade (RNMB): TOF ratio < 0.9. Risks: aspiration, hypoxia.
    • Objective monitoring (e.g., acceleromyography) is preferred.

Objective neuromuscular monitoring

⭐ Quantitative monitoring (e.g., acceleromyography) showing a TOF ratio > 0.9 is the gold standard for confirming adequate recovery from NMBAs and readiness for extubation.

High‑Yield Points - ⚡ Biggest Takeaways

  • Succinylcholine: Rapid onset/offset; triggers malignant hyperthermia, risk of hyperkalemia.
  • Non-depolarizers: Competitive ACh antagonists; reversed by Neostigmine/Glycopyrrolate or Sugammadex (for rocuronium/vecuronium).
  • Atracurium/Cisatracurium: Hoffmann elimination; Cisatracurium has less histamine release.
  • Rocuronium: Alternative for Rapid Sequence Intubation (RSI).
  • Pancuronium: Long-acting; causes tachycardia (vagolytic).
  • Monitor with Train-of-Four (TOF); aim for 1-2 twitches.
  • Block potentiation: Inhalational agents, aminoglycosides, hypothermia, acidosis.

Practice Questions: Neuromuscular Blocking Agents

Test your understanding with these related questions

Probable indicators of reversal of neuromuscular blockade are all EXCEPT:

1 of 5

Flashcards: Neuromuscular Blocking Agents

1/10

Sugammadex is the antidote for non depolarising muscle relaxants except _____

TAP TO REVEAL ANSWER

Sugammadex is the antidote for non depolarising muscle relaxants except _____

Mivacurium

browseSpaceflip

Enjoying this lesson?

Get full access to all lessons, practice questions, and more.

Start Your Free Trial